TOBRADEX (tobramycin and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1988.
Drug data last refreshed 19m ago · AI intelligence enriched 1w ago
TOBRADEX is a fixed-dose ophthalmic ointment combining tobramycin (antibiotic) and dexamethasone (corticosteroid) for treating bacterial eye infections with inflammation. It works via corticosteroid hormone receptor agonism to reduce inflammation while the antibiotic addresses bacterial pathogens. The combination targets patients with moderate-to-severe ocular bacterial infections requiring dual anti-inflammatory and antimicrobial action.
Product is approaching loss of exclusivity with minimal Part D spending ($17K in 2023), indicating a mature, declining franchise with contracting commercial team investment.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Zylet vs TobraDex in Blepharokeratoconjunctivitis
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
Worked on TOBRADEX at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTOBRADEX has zero linked job openings, indicating minimal active hiring and a contracting franchise. Career opportunities are concentrated in legacy brand management and field sales roles focused on defending market share against generics and Novartis' own competitors (CIPRODEX, CIPRO HC, MAXITROL).